Panagora Asset Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-226,098
| Closed | -$2.53M | – | 2429 |
|
|
2017
Q3 | $2.53M | Sell |
226,098
-102,690
| -31% | -$1.13M | 0.01% | 774 |
|
|
2017
Q2 | $3.62M | Buy |
328,788
+68,966
| +27% | +$690K | 0.01% | 666 |
|
|
2017
Q1 | $2.55M | Buy |
259,822
+70,502
| +37% | +$704K | 0.01% | 788 |
|
|
2016
Q4 | $2.04M | Sell |
189,320
-96,513
| -34% | -$965K | 0.01% | 895 |
|
|
2016
Q3 | $2.93M | Buy |
285,833
+135,322
| +90% | +$1.47M | 0.01% | 739 |
|
|
2016
Q2 | $1.97M | Sell |
150,511
-12,638
| -8% | -$166K | 0.01% | 874 |
|
|
2016
Q1 | $1.79M | Buy |
163,149
+5,468
| +3% | +$48.6K | 0.01% | 909 |
|
|
2015
Q4 | $1.45M | Buy |
157,681
+35,291
| +29% | +$295K | 0.01% | 924 |
|
|
2015
Q3 | $849K | Buy |
122,390
+28,314
| +30% | +$242K | ﹤0.01% | 1106 |
|
|
2015
Q2 | $924K | Buy |
94,076
+79,473
| +544% | +$724K | ﹤0.01% | 1133 |
|
|
2015
Q1 | $129K | Hold |
14,603
| – | – | ﹤0.01% | 1857 |
|
|
2014
Q4 | $128K | Sell |
14,603
-14,602
| -50% | -$118K | ﹤0.01% | 1785 |
|
|
2014
Q3 | $201K | Hold |
29,205
| – | – | ﹤0.01% | 1632 |
|
|
2014
Q2 | $154K | Hold |
29,205
| – | – | ﹤0.01% | 1804 |
|
|
2014
Q1 | $133K | Hold |
29,205
| – | – | ﹤0.01% | 1858 |
|
|
2013
Q4 | $147K | Buy |
+29,205
| New | +$141K | ﹤0.01% | 1750 |
|
Panagora Asset Management's SCLN Position: Q4 2017 in Review
Panagora Asset Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 226,098 shares — an estimated $2.53M sold.
Panagora Asset Management first reported a position in SCLN in Q4 2013 and held it in 16 quarters. The position peaked at $3.62M in Q2 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Panagora Asset Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Panagora Asset Management sold 226,098 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $2.53M.
- Panagora Asset Management first reported a position in Sciclone Pharmaceuticals Inc in Q4 2013 and held it in 16 quarters.
- Panagora Asset Management's Sciclone Pharmaceuticals Inc position peaked at $3.62M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Panagora Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.